Multiple Sclerosis

Navigating treatment for multiple sclerosis and comorbid inflammatory diseases presents unique challenges, requiring careful, interdisciplinary strategies for optimal patient care.

Research highlights a strong link between Epstein-Barr virus and multiple sclerosis (MS), suggesting new therapeutic strategies targeting the virus for MS treatment.

A recent study reveals that over one-third of individuals with relapsing-remitting multiple sclerosis (MS) do not fully recover from relapses, highlighting critical recovery factors.

A study reveals that nearly 80% of US neurologists prescribing multiple sclerosis (MS) therapies received industry payments, influencing their prescribing patterns significantly.

New insights reveal how early intervention in radiologically isolated syndrome can delay multiple sclerosis (MS) onset and improve patient outcomes.

New findings demonstrate an association between increased cumulative depression genetic burden and multiple sclerosis (MS) disease activity.

Real-world studies reveal limited insights on infection risks for multiple sclerosis patients using disease-modifying treatments, highlighting gaps in clinical trial data.

Innovative therapies, including BTK inhibitors, target multiple sclerosis progression, offering hope for improved treatment outcomes and myelin repair.

Discover the latest advancements in multiple sclerosis (MS) treatment, including innovative therapies and strategies for disease prevention and repair.

Discover the latest insights on pediatric-onset multiple sclerosis, emphasizing early intervention and high-efficacy therapies for improved outcomes in children.

New biomarkers enhance multiple sclerosis (MS) diagnosis, enabling earlier detection and improved patient care, transforming MS management across the health care system.

Pediatric patients with multiple sclerosis (MS) face significant challenges transitioning to adult care, risking treatment delays and long-term health outcomes.

Vaccination against COVID-19 is crucial for individuals with multiple sclerosis (MS), ensuring safety and effectiveness despite immunosuppressive therapies.

Advancements in B-cell therapies, including anti-CD20 and anti-CD19 monoclonal antibodies, enhance treatment efficacy and safety for multiple sclerosis and autoimmune diseases.

Panelists discuss how current multiple sclerosis (MS) therapies show limited effectiveness against progression, but emerging Bruton tyrosine kinase (BTK) inhibitors offer promise by targeting both B cells and central nervous system (CNS)–penetrating microglia, with one showing a 31% reduction in confirmed disability progression in clinical trials.

Panelists discuss how chronic neuroinflammation involves distinct mechanisms from acute relapses—including microglial activation, mitochondrial dysfunction, and iron deposition—necessitating dual therapeutic approaches that address relapsing and progressive disease components.

Panelists discuss how robust clinical evidence from major studies like the EPIC and OPERA trials demonstrates that progression independent of relapse activity (PIRA) is the primary driver of confirmed disability progression in patients with multiple sclerosis (MS), with clinical parameters over 3 to 6 months being the most meaningful measures of treatment impact.

Panelists discuss how progression independent of relapse activity (PIRA) represents a distinct pathological process involving smoldering inflammation and neurodegeneration that drives disability in patients with multiple sclerosis (MS), particularly manifesting around midlife despite being present from disease onset.

The findings indicate that the currently approved 600-mg dose of intravenous ocrelizumab is optimal to significantly slow disability progression for patients with multiple sclerosis (MS).

National MS Education and Awareness Month is celebrated each year in the US in March, after having been launched in 2003 by MS Focus: the Multiple Sclerosis Foundation and affiliated groups.

In 2025, each issue of Population Health, Equity & Outcomes will feature a profile of a health system leader transforming care in their area of expertise. This issue spotlights a conversation with Kavita V. Nair, PhD, of the University of Colorado Anschutz Medical Campus.

Data from a systematic review of 30 real-world studies show comparable discontinuation rates of ocrelizumab to those in pivotal clinical trials among patients with different types of multiple sclerosis (MS).

Subcutaneous ocrelizumab (SC OCR) was found to be safe for patients with relapsing and primary progressive multiple sclerosis (RMS/PPMS).

Compared with healthy controls, patients with multiple sclerosis (MS) had higher odds of filling prescriptions for gabapentinoids and other anticonvulsants in the 5 years prior to MS onset.

The differences did not appear to be associated with potential moderating factors like age, sex, or smoking status.